Source comparison
GHRP-2 Acetate vs GHRP-6 Acetate: Research Application Comparison
Primary Mechanism GHS-R1a agonism with minimal peripheral ghrelin activation GHS-R1a agonism plus pronounced ghrelin receptor activation GHRP-6 engages dual pathways; GHRP-2 isolates somatotropic signalling Peak GH Release 6–9 ng/mL at 150–250 mcg dose 8–12 ng
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHS-R1a agonism with minimal peripheral ghrelin activation
- GHS-R1a agonism plus pronounced ghrelin receptor activation
- GHRP-6 engages dual pathways; GHRP-2 isolates somatotropic signalling
- Peak GH Release
- 6–9 ng/mL at 150–250 mcg dose
- 8–12 ng/mL at 100–200 mcg dose
- GHRP-6 generates 20–30% higher peak amplitude at lower doses
- Appetite Stimulation
- Minimal. <10% food intake variance
- Pronounced. 40–60% increase in post-dose food intake
- GHRP-6's ghrelin activity makes it unsuitable for studies controlling caloric intake
- Cortisol/Prolactin Co-Secretion
- Modest cortisol, minimal prolactin elevation
- Modest cortisol, moderate prolactin elevation
- GHRP-2 produces fewer secondary endocrine effects
- Ideal Research Context
- Anabolic signalling, lipolysis, IGF-1 studies where appetite is a confound
- GH-ghrelin interaction studies, appetite regulation, body composition with feeding variables
- Select based on whether ghrelin pathway activation serves the hypothesis or confounds it
- Dosing Frequency Tolerance
- Well-tolerated in multi-dose daily protocols without cumulative appetite effects
- Multi-dose protocols risk sustained caloric overconsumption
- GHRP-2 better suited for chronic dosing studies requiring dietary control